Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab

Abstract Aim Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate‐producing enterobacteria has been reported to enhance the efficacy of CPIs. However, the effects of enterob...

Full description

Bibliographic Details
Main Authors: Kazuhiro Nouso, Shohei Shiota, Rio Fujita, Akiko Wakuta, Kazuya Kariyama, Atsushi Hiraoka, Masanori Atsukawa, Joji Tani, Toshifumi Tada, Shinichiro Nakamura, Kazuto Tajiri, Masaki Kaibori, Masashi Hirooka, Ei Itobayashi, Satoru Kakizaki, Atsushi Naganuma, Toru Ishikawa, Takeshi Hatanaka, Shinya Fukunishi, Kunihiko Tsuji, Kazuhito Kawata, Koichi Takaguchi, Akemi Tsutsui, Chikara Ogawa, Hironori Ochi, Yutaka Yata, Hidekatsu Kuroda, Hiroko Iijima, Tomomitsu Matono, Noritomo Shimada, Satoshi Yasuda, Hidenori Toyoda, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
atezolizumab
bevacizumab
butyrate‐producing enterobacteria
hepatocellular carcinoma
Online Access:https://doi.org/10.1002/cam4.6416

Similar Items

Similar Items